FIELD: medicine; pharmaceutics.
SUBSTANCE: invention refers to medicine and pharmaceutics and discloses a method of treating a coronavirus disease, including caused by SARS-CoV-2, involving administering to a subject in need thereof an effective amount of ABC294640 in the form of a free base or in the form of a salt thereof.
EFFECT: using the invention enables the effective treatment of coronavirus diseases.
21 cl, 12 dwg, 5 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREVENTION OR TREATMENT OF CORONAVIRUS AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS | 2022 |
|
RU2794315C1 |
| MEFLOQUINE AND COMBINATIONS THEREOF FOR TREATING AND PREVENTING A CORONAVIRUS INFECTION | 2020 |
|
RU2763024C1 |
| METHOD FOR THE TREATMENT OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2775966C1 |
| METHODS OF TREATING CORONAVIRUS INFECTIONS | 2021 |
|
RU2825648C1 |
| THERAPEUTIC AGENT AGAINST CORONAVIRUS INCLUDING AN ELAEOCARPUS SYLVESTRIS EXTRACT | 2021 |
|
RU2780346C1 |
| METHOD OF TREATING COVID-19 USING OX40 (CD134) RECEPTOR AGONISTS | 2020 |
|
RU2826983C2 |
| PHILLYRIN AND ITS DERIVATIVES FOR SUPPRESSION OF THE 3CLPRO PROTEIN AND FIGHTING THE COVID-19 VIRUS | 2021 |
|
RU2804307C1 |
| AGENT FOR REDUCING RISK AND RELIEVING SYMPTOMS OF BETA-CORONAVIRUS INFECTION | 2021 |
|
RU2747890C1 |
| METHODS FOR TREATING INFECTIOUS DISEASES CAUSED BY CORONAVIRUS | 2021 |
|
RU2772701C1 |
| PEPTIDES WITH ANTIVIRAL ACTIVITY | 2024 |
|
RU2834861C1 |
